Published online Jul 14, 2023. doi: 10.3748/wjg.v29.i26.4099
Peer-review started: November 27, 2022
First decision: December 27, 2022
Revised: January 10, 2023
Accepted: March 20, 2023
Article in press: March 20, 2023
Published online: July 14, 2023
Processing time: 224 Days and 9.9 Hours
Coronavirus disease 2019 (COVID-19) has several extrapulmonary symptoms. Gastrointestinal (GI) symptoms are among the most frequent clinical manifestations of COVID-19, with severe consequences reported in elderly patients. Furthermore, the impact of COVID-19 on patients with pre-existing digestive diseases still needs to be fully elucidated, particularly in the older population. This review aimed to investigate the impact of COVID-19 on the GI tract, liver, and pancreas in individuals with and without previous digestive diseases, with a particular focus on the elderly, highlighting the distinctive characteristics observed in this population. Finally, the effectiveness and adverse events of the anti-COVID-19 vaccination in patients with digestive disorders and the peculiarities found in the elderly are discussed.
Core Tip: Gastrointestinal symptoms are frequent in coronavirus disease 2019 (COVID-19), with more severe consequences reported in elderly patients. Patients with pre-existing liver disease are at an increased risk for worse outcomes, while no definitive conclusions can be drawn regarding patients with inflammatory bowel disease or pancreatic diseases. Elderly patients with digestive disorders, although the available data are limited, have no worse COVID-19 outcomes than those without these diseases.